Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series

Gregory A Raczniak; Lisa R Bulkow; Michael G Bruce; Carolyn L Zanis; Richard L Baum; Mary M Snowball; Kathy K Byrd; Umid M Sharapov; Thomas W Hennessy; Brian J McMahon

doi:10.1093/infdis/jis710

Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series

J Infect Dis. 2013 Feb 1;207(3):493-6. doi: 10.1093/infdis/jis710. Epub 2012 Nov 29.

Authors

Gregory A Raczniak¹, Lisa R Bulkow, Michael G Bruce, Carolyn L Zanis, Richard L Baum, Mary M Snowball, Kathy K Byrd, Umid M Sharapov, Thomas W Hennessy, Brian J McMahon

Affiliation

¹ Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. graczniak@cdc.gov

Abstract

The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Adolescent
Adult
Alaska
Child
Child, Preschool
Follow-Up Studies
Hepatitis A / immunology*
Hepatitis A / prevention & control*
Hepatitis A Antibodies / blood
Hepatitis A Antibodies / immunology
Hepatitis A Vaccines / immunology*
Hepatitis A virus / immunology*
Humans
Young Adult

Substances

Hepatitis A Antibodies
Hepatitis A Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding